Frequently asked questions

Our research team at the Wal-yan Centre work side by side with research teams around the world. Phage WA are part of the national network of Phage Australia, working together to ensure the best possible outcomes for those suffering with AMR infections.

Phage WA researchers have isolated phages from environmental sources, such as wastewater and freshwater. However, phages are abundant and can often be found wherever the bacteria they infect may be. 

Many antibiotics affect several bacteria, not just the one causing the infection. While beneficial they can cause unwanted side effects including an upset stomach. Phage therapy can work as a personalised treatment by specifically targeting the causative species of the infection with high precision. Phages also act upon bacteria that antibiotics cannot because they are either in a protective shell called a biofilm or have developed resistance.

Furthermore, phages will not damage other organs, like the liver or kidneys, which some antibiotics use over a very long time are known to do.

Phages are viruses and natural predators of bacteria. Humans routinely come into contact with them without being harmed.

Phage therapy was discovered before antibiotics, but it was quickly replaced in most countries because antibiotics were easy to make. Phage therapy has continued in Eastern European countries where antibiotics were not readily available, and most early phage therapy research has been performed in these countries.

A considerable amount of time is required to build a phage repository and generate the data needed to ensure the safe and effective use in humans. However, we have phages ready to be used against some of the highest priority bacteria. In collaboration with other research institutes all over the world working in this space, we can access phages against other dangerous bacteria.

Yes. Phages are specific to a bacteria and are not restricted to treat infection in only specific areas/ organs of the body. Phages effective against AMR bacteria isolated from the lung have been shown to be just as effective in treating the same bacteria that causes skin infections.

To begin, phage therapy will be available to those recommended by a doctor. Specifically, individuals without viable treatment options, including those whose infections are not being cleared by currently available antibiotics, or those who are allergic to antibiotics.

Once phage therapy becomes more established, it can become more widely available by conducting clinical trials where interested participants can enrol.

Phage therapy will be prioritised by people with the most serious lung infections. The selection criteria that clinicians consider include: lung function level, infection response to antibiotics and any antibiotic toxicity being experienced.

Eventually, phage therapy will be expanded to others who may be less clinically severe but still require other treatments.

Their immune system may need to be supported until the microbiome is restored. Extra precautions are taken to ensure phages are safe before they are even considered for therapy.

This includes looking at a phage’s genetic makeup, ability to kill bacteria and effects on human cells. Phages are specific for the bacteria they target, so they should not affect the rest of a person’s microbiome. They will also assist the immune system in removing a bacterial infection.

Phage therapy has been successfully performed in other countries without adverse events. Still, because it is not common practice, patient safety monitoring will be above what is currently achieved for antibiotics

Phage therapy will not replace antibiotics or any other treatments being provided. In fact, phages and antibiotics have been shown to work very well together and provide better treatment than either treatment alone.

Phages may also extend the usefulness of antibiotics by preventing resistance development over time. 

There have not been any serious side effects associated with phage therapy to date. The most serious side effect was when a patient experienced wheezing, shortness of breath, and fever controlled by medical staff.

Costs will vary depending on the type of infection that is being treated and how long the treatment will continue for. While the cost of phage therapy may seem high initially, when we consider the costs of trying to treat ongoing infections with treatments that are no longer effective, a single course of phage therapy is likely to be cheaper in the long run.

The first use of phage therapy in WA will be in those recommended by a doctor, either because they have infections that cannot be treated by antibiotics or because they have developed allergies that limit their treatment options.

Clinical trials will soon be underway to capture large-scale safety and effectiveness data which are necessary to make phage therapy more broadly used and available.